热门资讯> 正文

AgomAb Therapeutics NV报告1H结果

2026-08-07 22:16

AgomAb Therapeutics(AGMB) 0

AgomAb Therapeutics NV press release (AGMB): 1H Cash, cash equivalents and short-term cash investments totaled €252.0 million as of June 30, 2026.
Net loss was €31.0 million for the six months ended June 30, 2026, compared to €26.9 million for the six months ended June 30, 2025.

More on AgomAb Therapeutics NV

AgomAb Therapeutics: High Risk, High Reward Stock
Historical earnings data for AgomAb Therapeutics NV
Financial information for AgomAb Therapeutics NV

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。